17342-08-4

Basic information

• Product Name: L-Pyroglutaminol
• Synonyms: 2-Pyrrolidinone, 5-(hydroxyMethyl)-, (5S)-;L-Pyr-OL;(S)-5-(Hydroxymethyl)-2-pyrrolidinone,99%e.e.;(S)-(+)-5-(HYDROXYMETHYL)-2-PYRROLIDINONE;(S)-5-(HYDROXYMETHYL)-2-PYRROLIDINONE;TIMTEC-BB SBB004302;PYROGLUTAMINOL;PGLU-OL
• CAS NO: 17342-08-4
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.13
• EINECS: -0
• Product Categories: pharmacetical;Pyrrolidine series;Heterocyclic Compounds;Amides (Chiral);Chiral Building Blocks;Synthetic Organic Chemistry;Heterocycles;Miscellaneous Reagents
• Mol File: 17342-08-4.mol

Chemical Properties

• Melting Point: 79-80 °C(lit.)
• Boiling Point: 147-149°C 0,06mm
• Flash Point: 147-149°C/0.06m
• Appearance: White to light yellow/Crystals or Crystalline Powder
• Density: 1.1808 (rough estimate)
• Refractive Index: 31 ° (C=5, EtOH)
• Storage Temp.: Store at 0-5°C
• Solubility: DMSO, Ethanol, Methanol
• PKA: 14.35±0.10(Predicted)
• Water Solubility: Soluble in water.
• BRN: 4657914
• CAS DataBase Reference: L-Pyroglutaminol(CAS DataBase Reference)
• NIST Chemistry Reference: L-Pyroglutaminol(17342-08-4)
• EPA Substance Registry System: L-Pyroglutaminol(17342-08-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-37/39
• WGK Germany: 3
• F: 3-10
• Hazardous Substances Data: 17342-08-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
L-Pyroglutaminol is used as a key compound in organic synthesis for its ability to participate in a wide range of chemical reactions. Its unique chemical properties allow it to be a versatile building block in the creation of more complex molecules and structures.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, L-Pyroglutaminol is used as an intermediate in the synthesis of various drugs and medications. Its role in creating complex molecular structures makes it an essential component in the development of new and innovative pharmaceutical products.
Used in Chemical Research:
L-Pyroglutaminol is also utilized in chemical research as a tool to study and understand the behavior of different chemical reactions. Its unique properties and reactivity make it an ideal candidate for exploring new reaction pathways and mechanisms.

Upstream product

• 56-86-0 L-glutamic acid 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 4931-66-2 methyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 74936-93-9 (S)-5-oxopyrrolidine-2-carbonyl chloride 
• 6525-53-7 L-glutamic acid dimethyl ester 
• 1118-89-4 diethyl-L-glutamate hydrochloride 
• 142-47-2 glutamic acid sodium salt 
• 4931-66-2 (S)-5-Hydroxy-3,4-dihydro-2H-pyrrole-2-carboxylic acid methyl ester 

Downstream Products

• 51693-17-5 (S)-toluene-4-sulfonic acid 5-oxo-pyrrolidin-2-ylmethyl ester 
• 72478-99-0 (S)-4-Amino-5-hydroxypentanoic Acid 
• 72479-04-0 (-)-(5S)-5-(Chloromethyl)-2-pyrrolidinone 
• 72479-05-1 (S)-(-)-5-(Bromomethyl)-2-pyrrolidinone 
• 138-15-8 l-glutamic acid hydrochloride 
• 99208-71-6 (5S)-1-aza-2,2-dimethyl-3-oxa-8-oxo-bicyclo[3.3.0]octane 
• 141694-96-4 (+)-S-2-oxarolziracetam 
• 109063-57-2 acetic acid (S)-(5-oxo-2-pyrrolidinyl)methyl ester 
• 125629-92-7 (S)-1-benzyl-5-((benzyloxy)methyl)pyrrolidin-2-one 
• 105526-85-0 (S)-5-(trityloxymethyl)pyrrolidin-2-one 
• 153650-39-6 (C₅H₉)2POCH₂C₄H₅ONP(C₅H₉)2 
• 103201-79-2 (3R,7aS)-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 
• 1217546-92-3 (2R,SS)-2-phenyl-3-oxa-1-azabicyclo(3.3.0)octan-8-one 
• 94615-12-0 (S)-5-(methoxymethoxy)methyl-2-pyrrolidinone 

Relevant articles and documents

INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

N-Heterocyclic carbene triazolium salts containing brominated aromatic motifs: Features and synthetic protocol

In this work, we provide a brief overview of the role of N-aryl substituents on triazolium N-heterocyclic carbene (NHC) catalysis. This synopsis provides context for the disclosed synthetic protocol for new chiral N-heterocyclic carbene (NHC) triazolium salts with brominated aromatic motifs. Incorporating brominated aryl rings into NHC structures is challenging, probably due to the substantial steric and electronic influence these substituents exert throughout the synthetic protocol. However, these exact characteristics make it an interesting N-aryl substituent, because the electronic and steric diversity it offers could find broad use in organometallic- A nd organo-catalysis. Following the synthetic reaction by NMR guided the extensive modification of a known protocol to enable the preparation of these challenging NHC pre-catalysts.

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

Practical Synthesis of Chiral N-Heterocyclic Carbene Triazolium Salts Containing a Hydroxy Functional Handle

A library of functionalized chiral pyrrolidine-based N-heterocyclic carbene triazolium salts containing a hydroxy handle is prepared from readily accessible chiral (S)-pyroglutamic acid in eight steps. This improved synthetic protocol affords increased yields for known structures and 18 new NHCs are prepared by this method. The presence of a hydroxy handle offers potential for further functionalization and for non-covalent control over catalytic reactions in which the NHCs can serve as organocatalysts or ligands for organometallic catalysis.

Compounding method for LCZ696 midbody

The invention discloses a compounding method for a LCZ696 midbody. The compounding route is as follows: wherein R1 is Me, Et or i-Pr; X is Cl, Br or I; R2 is Ms, Ts or Tf. According to the compounding method for the LCZ696 midbody disclosed by the invention, the methylating difficulty is reduced, the midbody is configured and overturned through the consequent reaction, the proportion of the required configuration is greatly increased, the product yield, purity and use ratio are increased and the industrial large-scale production is benefited.

Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a serious and deadly disease for which treatment options are limited. The recent approval of antifibrosis agent nintedanib represents one of the first therapeutic approaches for the treatment of IPF. Here, we report novel indolinone-based multikinase inhibitors that target angiogenesis and fibrosis pathways and may serve as potential therapeutics for IPF. KBP-7018 is a novel, tyrosine kinase-selective inhibitor with potent effects on three fibrotic kinases (c-KIT, PDGFR, and RET). The pharmacokinetics (PK) properties of KBP-7018 were favorable in mice, rats, and dogs. In a bleomycin (BLM)-induced mouse pulmonary fibrosis model, 10, 30, and 100 mg/kg daily doses (q.d.) of KBP-7018 improved the 28-day survival rate in a dose-dependent manner. The improved efficacy of KBP-7018 compared to nintedanib provided a certain level of chemical validation for the involvement of PDGFR, c-KIT, and RET in IPF. Thus, KBP-7018 represents a novel multikinase inhibitor with differentiated activity, highly enhanced selectivity, and acceptable PK profiles that will enter phase I clinical trials.

Preparation method for L-hydroxyproline

The invention provides a preparation method for L-hydroxyproline. The preparation method comprises the following steps: preparing pyroglutamic acid; preparing pyroglutamate; preparing pyroglutamic acid alcohol; preparing (3R,7aS)-3-phenyltetrahydropyrrolo[1,2]oxazole-5(3H)-one; and preparing L-hydroxyproline. Compared with the prior art, the invention has the following beneficial effects: the method overcomes the problems that a traditional manner of extraction of L-hydroxyproline from an animal donor has potential safety hazards and that production of L-hydroxyproline is limited as biological raw materials are utilized, and can synthesize L-hydroxyproline under the condition of shortage of biological raw materials; synthetic methods for L-hydroxyproline are enriched; the added value of L-hydroxyproline is increased; the application scope of L-hydroxyproline can be further broadened; prepared L-hydroxyproline is high in yield and purity, so the synthesis purity of atazanavir is indirectly improved; and common raw materials can be selected in preparation of L-hydroxyproline, so production cost is low.

CERTAIN PROTEIN KINASE INHIBITOR

Provided are certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

As tyrosine kinase inhibitors substituted indolinone derivatives

The invention belongs to the technical field of a medicine, and particularly relates to a substituted indole ketone derivative as a tyrosine kinase inhibitor shown in a general formula (I), a pharmaceutically acceptable salt, a deuterated article or a stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, Rc, Rd, n, n1, n2, n3, n4, a ring A and a ring B are defined in the specification. The invention also relates to a preparation method of the compound, a drug preparation containing the compound, and application of the compound in preparation of a drug for preventing or treating a fibrosis disease and treating an excessive hyperplasia disease.